A New Era Dawns in Physician-Device Industry Relationships
The push for transparency in the health care industry has moved beyond initial regulations focused on hospital safety disclosures and is now taking on longstanding marketing practices by manufacturers. This time, money trails are the focal point, and if medical device manufacturers start to feel as if someone is spying over their shoulders, it may be more than paranoid imaginations at work. A growing list of regulations and "codes of conduct" are popping up with guidelines for any type of gratuity passing from manufacturers to physicians or hospitals. These new laws and rules are meant to be stringent and they will impact every manufacturer in the device industry.
by Robert Neil
The push for transparency in the health care industry has reached an almost all-encompassing point that’s moving beyond initial regulations focused on hospital safety disclosures and is now taking on...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
Editor’s note: This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.
Editor’s note: We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in coverage topics, content format or the method in which you receive and access Medtech Insight, or if you love it how it is, now is the time to have your voice heard.
Medtronic announced it received expanded MRI labeling for its DBS systems, which is critical, given that almost 70% of all DBS-eligible patients will likely need an MRI at some point in their care, says Ashwini Sharan, CMO for Medtronic Neuromodulation.
In this episode, Medtech Insight reporter Natasha Barrow speaks to LungLife AI CEO Paul
Pagano. Lung Life AI is a US-based AIM-listed medical technology company that has developed a liquid biopsy test for the early detection of lung cancer called Lung LB. Pagano runs through the highlights of Lung Life AI journey to date and its future ambition for a strategic partnership. He also provides advice to similar diagnostic companies seeking reimbursement andcompliance with the US FDA Lab Developed Test ruling.
During MD&M East last week, regulatory consultant Darren Reeves reminded device manufacturers that the time to get ready to comply with the new Quality Management System Regulation is now.
Handheld diagnostics are more powerful, accessible and clinically relevant than ever. Medtech Insight spoke to companies behind such technologies to learn how they work and discuss their commercial models.
